Skip to main content

Table 1 Pathological and clinical data of the arrayed prostate cancers

From: PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer

  Study cohort on TMA (n = 13,660) Biochemical relapse among category
Follow-up   
 n 12,208 3017 (25%)
 Mean / median 58.8 / 48.5 months
Age (y)   
 ≤50 352 61 (17%)
 51–59 3335 701 (21%)
 60–69 7827 1747 (22%)
 ≥70 2093 508 (24%)
Pretreatment PSA (ng/ml)  
 < 4 1694 252 (15%)
 4–10 8195 1464 (18%)
 10–20 2763 847 (31%)
 > 20 922 442 (48%)
pT stage (AJCC 2002)   
 pT2 8861 1030 (12%)
 pT3a 2984 958 (32%)
 pT3b 1696 976 (58%)
 pT4 71 53 (75%)
Gleason grade   
 ≤3 + 3 2888 236 (8%)
 3 + 4 7286 1269 (17%)
 3 + 4 Tertiary 5 573 133 (23%)
 4 + 3 1301 594 (46%)
 4 + 3 Tertiary 5 868 380 (44%)
 ≥4 + 4 733 404 (55%)
Nodal (pN) stage   
 pN0 7904 1896 (24%)
 pN+ 856 524 (61%)
Surgical margin (R) status  
 Negative 10,962 1939 (18%)
 Positive 2649 1078 (41%)
  1. NOTE: Numbers do not always add up to 13,660 in the different categories because of cases with missing data. Abbreviation: AJCC American Joint Committee on Cancer